Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | KEAP1 loss |
Therapy | Buthionine sulfoximine + Radiotherapy |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KEAP1 loss | lung adenocarcinoma | sensitive | Buthionine sulfoximine + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, Buthionine sulfoximine (BSO) increased sensitivity of KEAP1 knockout non-small cell lung cancer cells to radiotherapy in culture (PMID: 33071215). | 33071215 |
PubMed Id | Reference Title | Details |
---|---|---|
(33071215) | KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition. | Full reference... |